EUVIMEDEUVIMED entdecken
Scoping Review

The clinical toxicity of advanced therapy medicinal products

Fraser J H Henderson iD, Simon L Hill

British Journal of Clinical Pharmacology · 2025-08 · 91 (8) · 2222-2240

DOI: 10.1002/bcp.70104 ↗

Kurz gefasst

Scoping Review in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 12.06.2025. Verfasst von Fraser J H Henderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Therapeutics, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Hauptthemen laut MEDLINE: Cell- and Tissue-Based Therapy, Genetic Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 149 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Advanced Therapy Medicinal Products (ATMPs) use genes, tissues or cells to offer transformative treatments for a range of diseases. They are associated with different safety challenges when compared to established therapeutics, such as small chemical entities or monoclonal antibodies, due to immunogenicity, off‐target effects and organ‐specific toxicities. This review evaluates the current clinical evidence on ATMP toxicity, highlighting key mechanisms of toxicity and describing approaches to risk management.

Methods

A scoping review was conducted using the MEDLINE and Embase databases to identify studies reporting toxicities associated with gene therapy medicinal products (GTMPs), somatic‐cell therapy medicinal products, tissue‐engineered products and combined ATMPs. Data were extracted and collated qualitatively, focusing on acute and chronic clinical toxicity.

Results

Acute toxicity, such as cytokine release syndrome and immune effector cell‐associated neurotoxicity syndrome were most often reported in GTMPs, particularly chimeric antigen receptor T‐cell therapies. Chronic risks of GTMPs include genotoxicity and tumorigenicity, especially with high‐dose adeno‐associated virus‐based therapies. Somatic‐cell therapy medicinal products carry risks of immunological toxicity and tumour formation, particularly in stem cell‐based approaches. Tissue‐engineered products present challenges of biocompatibility, scaffold degradation and host integration. Management strategies to mitigate anticipated toxicity include preconditioning regimens, safer vector design, immunosuppressive therapies (e.g. tocilizumab) and long‐term monitoring.

Conclusion

ATMPs offer significant therapeutic promise but require robust safety assessments and proactive risk management plans to address their complex potential toxicity profiles. Personalized approaches, advanced preclinical models and stringent regulatory oversight are essential to ensure these therapies fulfil their potential without compromising patient safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell- and Tissue-Based TherapyGenetic TherapyAnimalsHumansCytokine Release SyndromeRisk ManagementTissue Engineering

Stichwörter der Autor:innen

advanced therapy medicinal productscombined advanced therapy medicinal productscytokine release syndromegene therapy medicinal productssomatic‐cell therapy medicine productstissue‐engineered productstoxicity

Autor:innen und Institutionen

  • Clinical Pharmacology and Therapeutics, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne, UK.

ORCID-Profile: Fraser J H Henderson

Zitieren

APA

Henderson, F. J. H., & Hill, S. L. (2025). The clinical toxicity of advanced therapy medicinal products. British Journal of Clinical Pharmacology, 91(8), 2222-2240. https://doi.org/10.1002/bcp.70104

Vancouver

Henderson FJH, Hill SL. The clinical toxicity of advanced therapy medicinal products. British Journal of Clinical Pharmacology. 2025;91(8):2222-2240. doi:10.1002/bcp.70104

BibTeX
@article{Henderson2025,
  author = {Henderson, Fraser J H and Hill, Simon L},
  title = {The clinical toxicity of advanced therapy medicinal products},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {8},
  pages = {2222--2240},
  doi = {10.1002/bcp.70104}
}
Kostenlos starten →